The objective of this study is to evaluate the pharmacokinetics of deferiprone and its 3-O-glucuronide metabolite following administration of a single 1500 mg dose of Ferriprox in patients with sickle cell disease. The study, sponsored by ApoPharma, starts in May 2013 and the expected completion date is July 2013.

More information: clinicaltrials.gov, ITHANET Clinical Trials